Vanguard Group Inc. Boosts Position in LivaNova PLC (NASDAQ:LIVN)

Vanguard Group Inc. increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 12.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,349,887 shares of the company's stock after purchasing an additional 265,291 shares during the quarter. Vanguard Group Inc. owned approximately 4.33% of LivaNova worth $108,823,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Xponance Inc. raised its position in shares of LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after buying an additional 445 shares in the last quarter. Swiss National Bank grew its position in LivaNova by 0.7% in the fourth quarter. Swiss National Bank now owns 106,819 shares of the company's stock worth $4,947,000 after acquiring an additional 700 shares in the last quarter. Central Pacific Bank Trust Division increased its stake in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Amalgamated Bank raised its position in LivaNova by 3.0% during the fourth quarter. Amalgamated Bank now owns 24,900 shares of the company's stock valued at $1,153,000 after purchasing an additional 729 shares during the period. Finally, Rhumbline Advisers raised its position in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares during the period. Institutional investors own 97.64% of the company's stock.

LivaNova Stock Performance

LIVN stock traded down $0.18 during midday trading on Friday, hitting $33.96. 942,766 shares of the stock traded hands, compared to its average volume of 626,679. The stock's fifty day simple moving average is $41.37 and its 200-day simple moving average is $47.28. The firm has a market cap of $1.85 billion, a P/E ratio of 80.86 and a beta of 0.90. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Wall Street Analysts Forecast Growth

Several research analysts have commented on LIVN shares. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.